Ibrolipim

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameIbrolipim
Drug Alias NameNO-1886
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLipoprotein lipase stimulants
TargetsLipoprotein lipase
Therapy Area/IndicationsObesityHypertriglyceridemiaHypoalphalipoproteinemias
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsObesityHypertriglyceridemiaHypoalphalipoproteinemias

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG